ClinicalTrials.gg
RecruitingNCT06507618POWER IIUpdated Jun 30, 2026

Pre-Operative Window of ET to Inform RT Decisions (POWER II)

A Phase 3 interventional study of Tamoxifen, Letrozole, Anastrozole, or Exemestane in Breast Cancer Female, sponsored by University of Virginia. Recruiting at 6 sites in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by University of Virginia · Phase 3, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
65 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Breast Neoplasms by University of Virginia — 6 open to participants now, 7 under way, 2 of them phase 3. Breast Neoplasms · University of Virginia.

Planned enrollment
2nd of 17
354 · median 45
Started
2024
with 1 other
Phase 3
Only one
of the 18
Registered
14th of 18
by date

Among the 18 studies in Breast Neoplasms by University of Virginia, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2024, is the only one in phase 3, and was the 14th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 18 studies in Breast Neoplasms by University of Virginia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 65 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Breast Neoplasms by University of Virginia, or all of them as a file.
02

Study summary

This is a Phase III, multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated randomly assigned to one of two groups:

Intervention, treated with 3 months of pre-operative endocrine therapy (pre-ET) OR Control, participants follow standard of care and proceed directly to breast cancer surgery.

Both arms will be assessed for tolerance and compliance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).

Read the detailed description

Early-stage, estrogen receptor positive (ER+) breast cancer is traditionally treated with breast conserving surgery (BCS), radiation therapy (RT) and 5-10 years of adjuvant endocrine therapy (AET). Radiation therapy (RT) omission is an established treatment paradigm for women 65 years and older with ER+, node negative, small (≤ 3 cm) breast cancer. Despite the option for RT omission being recommended in the National Comprehensive Cancer Network (NCCN) guidelines, multiple modern studies demonstrate that a majority of older women still receive RT, raising concern for over-treatment. Conversely, there are a portion of patients who choose to omit RT but are not able to tolerate AET and thus are at risk for under-treatment and worse oncologic outcomes.

In the POWER I trial, patients were treated with 90 days of pre-operative endocrine therapy (pre-ET) as a window to establish endocrine therapy (ET) tolerance. The POWER I trial prospectively validated 90 days of pre-operative ET to determine if it could be used as a tool to inform adjuvant RT decisions and recommendations by patients and physicians respectively. Ninety days of pre-ET was shown to influence patient and physician preferences regarding adjuvant RT.

In the POWER II trial, participants will be randomized to treatment on either a) an intervention arm consisting of a 90-day window of pre-ET or b) the standard of care (control) arm in which participants proceed directly to BCS. In both arms, the decision to omit or administer adjuvant RT will be made by the treating physicians and patients. While not required per protocol, all patients will be recommended for AET if deemed appropriate by their oncologist, and adherence through 2 years will be monitored. The POWER I study revealed that pre-ET impacts patients' and physicians' decisions regarding adjuvant therapy and facilitates adjuvant therapy decisions that meld patient preferences and side effect tolerance. The purpose of the POWER II study is to examine whether 90 days of pre-ET results in a decrease in the number of (1) patients being treated with BCS alone and (2) patients treated with BCS+RT+AET. Adherence to AET will be defined as taking AET at 2 years post-BCS.

03

Conditions studied

  • Breast Cancer Female

Browse trials for

Keywords

  • breast cancer
  • endocrine therapy
  • radiation
  • letrozole
  • anastrozole
  • exemestane
  • tamoxifen
  • survey
  • questionnaire
  • geriatric
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ER+, PR +/-, and - non amplified invasive breast cancer and clinically negative nodes
  • performance status 0-2
  • Females, aged ≥ 65 years
  • Patient is eligible for BCS and opted for BCS
  • Patient is a candidate for radiation therapy
  • Patient is a candidate for endocrine therapy (tamoxifen or an aromatase inhibitor)
  • Ability to take oral medication and be willing to adhere to endocrine therapy for the 3-month period prior to BCS
  • Agreement to adhere to Lifestyle Considerations (details in protocol) throughout study duration
  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Bilateral synchronous breast cancer
  • Multicentric disease
  • Prior use of Tamoxifen or aromatase inhibitors
  • History of ipsilateral breast radiation therapy
  • Has a known additional that is progressing and/or requires active treatment with cytotoxic chemotherapy or radiation therapy. Malignancies deemed stable and low risk for complication per investigator's judgment may be allowed after discussion with multi-site PI.
  • Current or planned use of a strong CYP2D6 inhibitor (e.g., Fluvoxamine, Paroxetine) and is not able to receive an endocrine therapy agent that does not use the CYP2D6 pathway.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
354 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    90 days of pre-ET (endocrine therapy - tamoxifen or aromatase inhibitor) before Breast Cancer Surgery

    Drug: Tamoxifen, Letrozole, Anastrozole, or Exemestane

  • No intervention
    Control Arm

    Will proceed directly to Breast Cancer Surgery

Interventions

  • DrugTamoxifen, Letrozole, Anastrozole, or Exemestane

    Choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist.

    Also known as: Endocrine Therapy

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Proportion of participants who omit Radiation Therapy (RT) and are non-adherent to Endocrine Therapy (ET)

    Proportion of participants who omit RT and are non-adherent to ET as measure through the 24-month adjuvant follow-up visit

    Time frame: 24 months

  2. Proportion of participants who are treated with Breast Cancer Surgery (BCS) + RT + AET

    Proportion of participants who are treated with BCS + RT + AET as measured through the 24-month adjuvant follow-up visit

    Time frame: 24 months

Secondary outcomes

  1. Treatment with pre-ET and its impact on Decision Conflict

    Using Patient Reported Outcomes (PRO) assessments of Decisional Conflict Scale (DCS) to determine whether treatment with pre-ET lessens Decision Conflict. The DCS is a validated measure of patient perceptions of uncertainty surrounding treatment choices. The minimum score is a 0, which is interpreted as no decisional conflict, and the maximum score is 64, which is interpreted as the highest decisional conflict.

    Time frame: 24 months

  2. Treatment with pre-ET and its impact on Decision Regret

    Using Patient Reported Outcomes (PRO) assessments of Decision Regret Scale (DRS) to determine whether treatment with pre-ET lessens Decision Regret. The DRS is a validated, 5-item scale that measures self-reported regret after health care decisions. DRS scores range from 0 (no regret) to 100 (high regret).

    Time frame: 24 months

  3. Assessing whether patient's final treatment correlates with their beliefs about breast cancer

    Using the PRO assessment "Beliefs about Illness Questionnaire (BIP-Q)" to determine patient's beliefs about breast cancer. The BIP-Q is a validated survey to assess cognitive and emotional perceptions of illness.

    Time frame: 7 months

  4. Assessing whether patient's final treatment correlates with their beliefs about breast cancer

    Using the PRO assessment "Beliefs about Medicine Questionnaire (BMQ)" to determine patient's beliefs about breast cancer. The BMQ is a validated survey designed to capture patients' perceptions about medicines and medicine adherence.

    Time frame: 7 months

  5. Assessing whether patient's final treatment correlates with their beliefs about breast cancer

    Using the PRO assessment "Perceived Sensitivity to Medicine (PSM)" to determine patient's beliefs about breast cancer. The PSM is a validated 5-question survey designed to capture patients' opinions regarding their sensitivity to medications.

    Time frame: 7 months

  6. Assessing whether treatment with pre-ET leads to improved Health Related Quality of Life compared to those treated with standard of care

    Using PRO Assessments: EORTC Quality of Life questionnaires (QLQ-C30) to determine whether treatment with pre-ET leads to improved health-related quality of life compared to those treated with standard of care

    Time frame: 24 months

  7. Assessing whether early side effects of ET correlate with patient treatment group within study arms

    Using the PRO Assessment "Breast Cancer Prevention Trial Symptom Checklist (BCPT-SCL)" to assess whether early side effects of ET correlate with patient treatment group within study arms

    Time frame: 24 months

  8. Assessing whether early side effects of ET correlate with patient treatment group within study arms

    Using the PRO Assessment "Center for Epidemiologic Study Depression Scale Revised (CESD-R)" to assess whether early side effects of ET correlate with patient treatment group within study arms

    Time frame: 24 months

  9. To obtain data on local recurrence

    Local recurrence as measured through the 5 year adjuvant follow-up period

    Time frame: 5 years

  10. To obtain data on regional recurrence

    Regional recurrence as measured through the 5 year adjuvant follow-up period

    Time frame: 5 years

  11. To obtain data on contralateral breast cancer

    Contralateral breast cancer as measured through the 5 year adjuvant follow-up period

    Time frame: 5 years

  12. To obtain data on distant metastases

    Distant metastases as measured through the 5 year adjuvant follow-up period

    Time frame: 5 years

  13. To obtain data on disease free survival

    Disease free survival (DFS) as measured through the 5 year adjuvant follow-up period

    Time frame: 5 years

  14. To obtain data on cancer specific survival

    Cancer specific survival as measured through the 5 year adjuvant follow-up period

    Time frame: 5 years

  15. To obtain data on overall survival

    Overall survival (OS) as measured through the 5 year adjuvant follow-up period

    Time frame: 5 years

07

Study locations

6 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2029, 59 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 59 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2024
First posted
Jul 18, 2024
StartActual
Jul 19, 2024
Primary completionEst.
Jun 30, 2029
CompletionEst.
Mar 1, 2034
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06507618
Responsible party
Shayna Showalter, MD (Associate Professor, University of Virginia) — Principal investigator
First posted
Jul 18, 2024
Start date
Jul 19, 2024
Primary completion
Jun 30, 2029 (estimated)
Completion
Mar 1, 2034 (estimated)
Last update
Jun 30, 2026

Study contacts

Meagan Miller
Contact
aey8fc@uvahealth.org
434-243-8101
Shayna L Showalter, MD
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Exemestane

Start the discussion